176 related articles for article (PubMed ID: 21267570)
1. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
Pollmann S; Stensland M; Halvorsen EH; Sollid LM; Kvien TK; Fleckenstein B; Molberg O
Rheumatol Int; 2012 May; 32(5):1271-6. PubMed ID: 21267570
[TBL] [Abstract][Full Text] [Related]
2. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
[TBL] [Abstract][Full Text] [Related]
3. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.
Halvorsen EH; Pollmann S; Gilboe IM; van der Heijde D; Landewé R; Ødegård S; Kvien TK; Molberg Ø
Ann Rheum Dis; 2008 Mar; 67(3):414-7. PubMed ID: 18006540
[TBL] [Abstract][Full Text] [Related]
4. Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis.
Ishigami A; Uchida Y; Miyazaki T; Handa S; Choi EK; Kim YS; Kasahara Y; Maruyama N
Mod Rheumatol; 2013 Jul; 23(4):794-803. PubMed ID: 22986904
[TBL] [Abstract][Full Text] [Related]
5. Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Navarro-Millán I; Darrah E; Westfall AO; Mikuls TR; Reynolds RJ; Danila MI; Curtis JR; ; Rosen A; Bridges SL
Arthritis Res Ther; 2016 Oct; 18(1):241. PubMed ID: 27770831
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
[TBL] [Abstract][Full Text] [Related]
7. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
[TBL] [Abstract][Full Text] [Related]
8. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.
Harris ML; Darrah E; Lam GK; Bartlett SJ; Giles JT; Grant AV; Gao P; Scott WW; El-Gabalawy H; Casciola-Rosen L; Barnes KC; Bathon JM; Rosen A
Arthritis Rheum; 2008 Jul; 58(7):1958-67. PubMed ID: 18576335
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
10. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
Cappelli LC; Konig MF; Gelber AC; Bingham CO; Darrah E
Arthritis Res Ther; 2018 Mar; 20(1):59. PubMed ID: 29566742
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
Darrah E; Giles JT; Davis RL; Naik P; Wang H; Konig MF; Cappelli LC; Bingham CO; Danoff SK; Andrade F
Front Immunol; 2018; 9():2696. PubMed ID: 30515171
[No Abstract] [Full Text] [Related]
12. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
[TBL] [Abstract][Full Text] [Related]
14. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
[TBL] [Abstract][Full Text] [Related]
15. Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis.
Gómez-Bañuelos E; Shi J; Wang H; Danila MI; Bridges SL; Giles JT; Sims GP; Andrade F; Darrah E
Arthritis Rheumatol; 2022 Nov; 74(11):1746-1754. PubMed ID: 35675168
[TBL] [Abstract][Full Text] [Related]
16. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
[TBL] [Abstract][Full Text] [Related]
17. Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis.
Kobayashi T; Ito S; Kobayashi D; Shimada A; Narita I; Murasawa A; Nakazono K; Yoshie H
PLoS One; 2016; 11(4):e0154182. PubMed ID: 27111223
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
Zhao J; Zhao Y; He J; Jia R; Li Z
J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
[TBL] [Abstract][Full Text] [Related]
19. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity.
Darrah E; Giles JT; Ols ML; Bull HG; Andrade F; Rosen A
Sci Transl Med; 2013 May; 5(186):186ra65. PubMed ID: 23698378
[TBL] [Abstract][Full Text] [Related]
20. The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities.
Assohou-Luty C; Raijmakers R; Benckhuijsen WE; Stammen-Vogelzangs J; de Ru A; van Veelen PA; Franken KL; Drijfhout JW; Pruijn GJ
Biochim Biophys Acta; 2014 Apr; 1844(4):829-36. PubMed ID: 24594197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
